Scientists test powerful immune therapy to stop blood cancer before it starts
NCT ID NCT05767359
Summary
This study is testing whether a CAR-T cell therapy called cilta-cel can safely and effectively treat people with high-risk smoldering myeloma—an early, pre-cancerous stage of multiple myeloma. Researchers will collect and modify participants' own immune cells to target and destroy the abnormal plasma cells. The goal is to see if this treatment can control the disease before it progresses to active, symptomatic cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMOLDERING MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
Conditions
Explore the condition pages connected to this study.